Since albumin in plasma is mainly responsible for the colloid osmotic pressure and, as the main carrier protein, has antioxidant and anti-inflammatory properties, the therapeutic efficacy of albumin can be enhanced by correcting low levels of serum albumin during volume therapy; that is, hypoalbuminemia is corrected by raising serum albumin levels to ≥30 g/L [10]. The gene discussed is ALB; the disease is Hypoalbuminemia.